4 Readmission Predictors after Successful TAVR

4 Readmission Predictors after Successful TAVRReadmissions are frequent after cardiovascular procedures and they significantly increase healthcare costs. Data on readmission need within the first month after successful transcatheter aortic valve replacement (TAVR) are limited.

 

The registry included all TAVR patients surviving index hospitalization between January and February 2013 for readmission incidence, predictors, causes and costs within 30 days.

 

Of 12,221 included patients, 2,188 (17.9%) required readmission within 30 days.

 

Readmission predictors were:

  • length of stay longer than 5 days during index hospitalization
  • kidney injury (both acute and chronic)
  • transapical access
  • chronic lung disease

 

61.8% of these was due to non-cardiac causes and the remaining 38.2% was due to cardiac causes. Respiratory causes (14.7%), infections (12.8%), bleeding (7.6%) and peripheral vascular disease (4.3%) were the most common among non-cardiac causes, while heart failure (22.5%) and arrhythmia was the most common among cardiac causes (6.6%).

 

Readmissions median length was four more days.

 

Conclusion

Readmissions at 30 days after TAVR are frequent and are associated with comorbidities, access site and complications during index hospitalization. These predictors could alert about patients at high risk of readmission and prevent major complications.  

 

Original Title: Thirty-Day Readmissions after Transcatheter Aortic Valve Replacement in the United States. Insights from the Nationwide Readmissions Database.

Reference: Dhaval Kolte et al. Circ Cardiovasc Interv. 2017 Jan;10(1).


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....